Article Text

Download PDFPDF

Effect of a combination of telmisartan and amlodipine in hypertensive dogs
  1. Alicia Caro-Vadillo1,
  2. Maria Angeles Daza-González2,
  3. Elisa Gonzalez-Alonso-Alegre1,
  4. Alfonso Rodríguez1 and
  5. José Gómez-García3
  1. 1Medicina y Cirugía Animal, Universidad Complutense de Madrid, Madrid, Spain
  2. 2Hospital Clínico Veterinario Complutense, Universidad Complutense de Madrid, Madrid, Spain
  3. 3Boehringer Ingelheim Espana SA, Sant Cugat del Valles, Spain
  1. Correspondence to Dr Alicia Caro-Vadillo; aliciac{at}


Systemic hypertension (SHT) in dogs is considered a health risk factor. Telmisartan is a well-known antihypertensive agent in humans. There are limited reports about its efficacy in dogs. Five dogs with primary and secondary SHT refractory to the combined treatment of benazepril and amlodipine had a successful control of systolic arterial blood pressure (SBP) when telmisartan was combined with amlodipine. SBP showed a significant reduction after any treatment, but only reached successful control when amlodipine plus telmisartan was administered (median SBP: 215 mmHg before treatment [min-max: 180–240 mmHg]; 180 mmHg for amlodipine plus benazepril treatment [min-max: 170–210 mmHg]; 142 mmHg after amlodipine plus telmisartan treatment [min-max: 120–165 mmHg]). This control remained stable in the long-term follow-up (average 5.2 months). In the cases reported, the telmisartan plus amlodipine treatment showed good efficacy in the control of SHT, regardless of cause, and was well tolerated in all patients.

  • telmisartan
  • systolic blood pressure
  • systemic hypertension

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

View Full Text

Statistics from


  • Contributors Conception or design of the work: ACV, MADG, JGG. Data collection: ACV, MADG, EGAA, AR. Data analysis and interpretation: ACV, MADG, JGG. Drafting the article: ACV, MADG, EGAA, AR, JGG. Critical revision of the article: ACV, JGG. Final approval of the version to be published: ACV, MADG, EGAA, AR, JGG.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests JGG is an employee of Boehringer Ingelheim Spain.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Further data is available upon reasonable request to the corresponding author.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.